Glucose and lipid metabolism regulation

Glucose and lipid metabolism regulation refers to the integrated physiological processes that maintain energy homeostasis by balancing the production, transport, and utilization of glucose and fatty acids. This regulation is coordinated across multiple organ systems, including the liver, adipose tissue, skeletal muscle, and pancreas, primarily through the actions of hormones like insulin and glucagon (MDPI, 2022; UCL Discovery, 2017). At the cellular level, these pathways are managed by a network of nutrient sensors such as AMP-activated protein kinase (AMPK), metabolic enzymes, and nuclear receptors like Peroxisome proliferator-activated receptors (PPARs) that respond to metabolic demands (PMC, 2019; Journal of Endocrinology, 2020). Chronic dysregulation of these mechanisms leads to metabolic syndrome, type 2 diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD) (PMC, 2023; MDPI, 2022). Therapeutic strategies target various nodes in this network to restore metabolic balance; for example, GLP-1 receptor agonists enhance insulin secretion, while statins lower cholesterol synthesis (Preprints, 2022; UCL Discovery, 2017). Because the term describes a systemic biological process involving numerous distinct molecular entities rather than a single protein or receptor, it is classified as a physiological category rather than a discrete therapeutic target (PMC, 2023; Journal of Endocrinology, 2020).

Other names

Glucose and lipid homeostasisMetabolic regulationEnergy metabolism regulationGlycolipid metabolism

Pharmacological intervention in glucose and lipid metabolism regulation occurs through the modulation of specific molecular targets within the metabolic network. Key mechanisms include the activation of energy-sensing pathways (e.g., AMPK activation by metformin), the stimulation of incretin receptors (e.g., Glucagon-like peptide-1 receptor agonism by semaglutide), the activation of nuclear receptors that control gene transcription (e.g., PPAR activation by thiazolidinediones and fibrates), and the inhibition of rate-limiting enzymes or transporters (e.g., HMG-CoA reductase inhibition by statins or SGLT2 inhibition by gliflozins).